Biotech & pharma press releases — Press Release Database

Finance · Healthcare

CAPR 10-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline

San Francisco, California--(September 18, 2026) - Hagens Berman Sobol Shapiro LLP-a national plaintiffs' rights law firm with a premier securities practice group-notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the ongoing securities class action. This alert follows the U.S. Food and Drug Administration's (FDA) recent decision to extend the review period for Capricor's Biologics License Application...

Sep 18 · 19:42Newsfile

Finance · Biotech & pharma

IBN Initiates Coverage of Apimeds Pharmaceuticals US, Inc.

AUSTIN, Texas, Sept. 18, 2026 -- via IBN – Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) has engaged IBN, a multifaceted financial news and publishing company serving private and public entities, to assist with its corporate communications strategy.

Sep 18 · 18:00GlobeNewswire

Healthcare · Biotech & pharma

U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

Inluriyo plus Verzenio delivers proven clinical benefit after the evidence-based practice of maximizing initial treatment with an aromatase...

Sep 18 · 17:54Eli Lilly and Company

AI · Biotech & pharma

NAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMed

ImpriMed combines ex vivo functional testing with multimodal AI to support personalized cancer treatment decisions and drug development The investment is part of ImpriMed's $10 million Series A2 bridge round as the company advances U.S. commercialization and expands into Asia NAVER D2SF...

Sep 18 · 15:00PR Newswire

Finance · Biotech & pharma

Lowey Dannenberg, P.C. is Investigating Aardvark Therapeutics, Inc. (NASDAQ: AARD) for Potential Violations of the Federal Securities Laws

Lowey Dannenberg, P.C. is Investigating Aardvark Therapeutics, Inc. (NASDAQ: AARD)

Sep 18 · 14:55GlobeNewswire

Biotech & pharma

UNCY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. -...

Sep 18 · 14:19Newsfile

Finance · Biotech & pharma

Kaplan Fox Alerts ARS Pharmaceuticals Inc. (SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026

New York, New York--(September 18, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in ARS and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox...

Sep 18 · 12:15Newsfile

Finance · Healthcare

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

SARASOTA, Fla., Sept. 18, 2026 -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class,...

Sep 18 · 12:13PR Newswire

Healthcare · Biotech & pharma

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company’s regulatory path toward NDA filing for gout program XRx-026 Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company’s regulatory path toward NDA filing for gout program XRx-026

Sep 18 · 12:05GlobeNewswire

Finance · Biotech & pharma

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

REDWOOD CITY, Calif., September 18, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined w

Sep 18 · 12:00Business Wire

Healthcare · Energy

Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements

Theralase® Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology PipelineThis Press Release adds omitted safety and prescribing information about Adstiladrin® (nadofaragene firadenovec-vncg)Toronto, Ontario--(September 18, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and...

Sep 18 · 11:00Newsfile